The U.S. Food and Drug Administration approved Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Reyvow is not indicated for the preventive treatment of migraine.
© American Academy of Pain Medicine. All Rights Reserved.
American Academy of Pain (AAMP) is a nonprofit, 501(c)(3) tax-exempt organization.
1705 Edgewater Drive, #7778
Orlando, FL 32804
Phone: (800) 917-1619 Ext. 102
Fax: (407) 749-0714
American Academy of Pain Medicine
